BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31

BIOMERICA INC

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026

$1.76−0.09 (-4.86%)

Close on Oct 19, 2026

Market cap: $5.80M
P/E (TTM): –
Dividend yield: –

Dividends

Biomerica has not reported a dividend

No dividend per share appears in Biomerica's annual filings since fiscal 2011.

Where these numbers come from

Parsed from the XBRL in Biomerica's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-8 reverse split on Aug 29, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BMRA.

Revenue growth-11.2% · median 8.5%

Gross margin0.9% · median 44.3%

Operating margin-125.2% · median -790.2%

Net margin-115.5% · median -1043.1%

Company	Revenue	Growth
ICCC	$30.68M	+8.5%
BMRA	$4.34M	-11.2%
VNRX	$2.46M	+86.3%
IMDX	$1.67M	-60.8%
NNNN	–	–
TRIB	–	–

Company

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: May 31
Employees: 17
Held by institutions: 2.7%
Auditor: HASKELL & WHITE LLP
SEC CIK: 73290

Advertisement
300 × 250